Test Price
850 AED✅ Home Collection Available
NAFLD Genetic Susceptibility Panel (PNPLA3 & TM6SF2 Genotyping) in UAE | 850 AED | 2026 DHA Guidelines
تحليل جينات PNPLA3 و TM6SF2 للكشف عن الاستعداد الوراثي لمرض الكبد الدهني غير الكحولي في الإمارات | 850 درهم | معتمد من هيئة الصحة بدبي
Precision genomic screening for the two most validated risk polymorphisms driving NAFLD progression – delivered with ISO‑certified home collection and telephonic clinical guidance.
Executive Summary
This advanced genetic panel directly targets the PNPLA3 (I148M) and TM6SF2 (E167K) polymorphisms, the two most validated risk alleles for non‑alcoholic fatty liver disease (NAFLD), non‑alcoholic steatohepatitis (NASH), and fibrosis progression. Conducted via real‑time PCR with Sanger confirmation under ISO 9001:2015‑certified protocols, our 850 AED test provides definitive genotyping from a single blood draw with home collection available. Every report includes a clinical interpretation call with a DHA‑licensed specialist and supports proactive, precision‑driven liver health management in accordance with UAE Prevention Law 2026.
ملخص تنفيذي: تم تصميم هذا الفحص الجيني المتقدم وفقًا لأحدث إرشادات هيئة الصحة بدبي لتحديد الاستعداد الوراثي لمرض الكبد الدهني غير الكحولي (NAFLD) بدقة تصل إلى 99.9%. يشمل الفحص سحب عينة دم منزلية مع نقل مبرد معتمد، وتحليل بتقنية تفاعل البوليميراز المتسلسل الكمي (qPCR) مع تأكيد سانجر، وتقرير مفصل مع استشارة هاتفية مجانية لتفسير النتائج. السعر 850 درهمًا فقط، والخدمة متوافقة تمامًا مع المرسوم الاتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية.
Overview
This genotyping test screens for the PNPLA3 rs738409 (I148M) and TM6SF2 rs58542926 (E167K) variants—genetic markers independently associated with a 3–5 fold increased risk of progressive NAFLD and hepatocellular carcinoma. By identifying high‑risk genotypes early, you and your physician can implement aggressive lifestyle modifications, pharmaconutritional interventions, and scheduled surveillance imaging long before irreversible fibrosis sets in.
| Feature | Our Test | Closest Alternative (Standard Liver Profile) |
|---|---|---|
| Precision | >99.9% sensitivity via qPCR + Sanger confirmation | ALT/AST only – no genetic risk quantification |
| Methodology | Real‑time PCR with allele‑specific probes, Sanger‑validated | Colorimetric/ enzymatic assays |
| Turnaround | Sample Mon/Thu by 9 AM → Report Wed/Sat | Often 24–48h; no genetic insight |
| Home Collection | 8 AM‑11 PM, all Emirates, cold‑chain transport | May require clinic visit |
| Post‑Test Support | Telephonic clinical guidance included | Often limited to automated report |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY, DHA‑licensed Consultant Gastroenterologist (DHA: 61713011), shares a direct clinical perspective:
“While the PNPLA3 and TM6SF2 genotypes provide invaluable risk stratification, they do not replace clinical evaluation; a normal genotype does not eliminate the possibility of NAFLD from environmental factors. We always interpret results in the context of liver enzymes, imaging, and metabolic health. This test empowers patients with actionable genetic insight—use it as a springboard for sustained lifestyle changes, not a deterministic verdict.”
⛔ Do not discontinue prescribed medication without consulting your doctor.
Safety & Exclusion Criteria
- Patients on anticoagulants must consult their physician prior to blood draw – minor bleeding risk.
- Not recommended for individuals with active hepatic decompensation or acute liver failure.
- Genetic testing for minors requires explicit parental consent and documented clinical necessity under UAE CDS Law 2026.
Emergency Red Flags: If you experience sudden severe right upper quadrant pain, jaundice, or confusion, proceed to the nearest emergency department immediately – do not wait for genetic test results.
Patient FAQ & Clinical Guidance
Q: What does the PNPLA3 & TM6SF2 genetic detect, and how can it influence my liver health plan?
ماذا يكشف اختبار جينات PNPLA3 و TM6SF2 وكيف يؤثر على خطة صحة الكبد؟
Snippet answer: This genetic panel identifies the two strongest inherited risk variants for progressive NAFLD, guiding personalized lifestyle and surveillance intensity. The results allow your gastroenterologist to classify your predisposition into low‑, moderate‑, or high‑risk categories. A high‑risk genotype may prompt earlier imaging, targeted nutrigenomic advice, and more frequent liver enzyme monitoring, while a normal result provides reassurance and focus on modifiable factors.
Q: Is home blood collection available across all Emirates, and how do I prepare?
هل يتوفر سحب الدم المنزلي في جميع الإمارات وكيف أستعد للفحص؟
Snippet answer: Our DHA‑licensed phlebotomists provide cold‑chain home collection in Dubai, Abu Dhabi, Sharjah, and all Emirates from 8 AM–11 PM; simply fast for 4 hours and hydrate well. A Genomics Clinical Information Requisition Form (Form 20) must be completed before the visit; we send it electronically. The sample is drawn into a lavender‑top EDTA tube and transported refrigerated to our central lab within 4 hours.
Q: Will my genetic data remain confidential under UAE law?
هل تبقى بياناتي الجينية سرية بموجب القانون الإماراتي؟
Snippet answer: Your DNA information is protected under Federal Decree‑Law No. 41 of 2024 and UAE PDPL, with encrypted storage and no third‑party sharing. All sequencing data are anonymized after reporting, stored on UAE‑based servers compliant with ISO 27001, and only accessible to you and the ordering physician with explicit consent. No genetic information is used for any purpose other than your clinical care.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians